Detalhe da pesquisa
1.
Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional study.
Lancet Oncol
; 25(4): 431-438, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38547890
2.
Impact of rarity on Canadian oncology health technology assessment and funding.
Int J Technol Assess Health Care
; : 1-6, 2020 Aug 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32779560
3.
Focused Jurisdictional Scan of Glomerulonephritis Medication Access in Canada: A Program Report.
Can J Kidney Health Dis
; 10: 20543581231190227, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37581108
4.
Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
Curr Oncol
; 30(4): 3776-3786, 2023 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37185399
5.
Comparison of Use of Neoadjuvant Systemic Treatment for Breast Cancer and Short-term Outcomes Before vs During the COVID-19 Era in Ontario, Canada.
JAMA Netw Open
; 5(8): e2225118, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35917122
6.
Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario.
Curr Oncol
; 28(2): 1056-1066, 2021 02 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-33652898
7.
Are population-based patient-reported outcomes associated with overall survival in patients with advanced pancreatic cancer?
Cancer Med
; 9(1): 215-224, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31736256